FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor
On November 10, 2026, the FDA approved pimicotinib (Pimjetmi, EMD Serono, Inc.) for adults with symptomatic TGCT for whom surgical resection may cause worsening functional limitation or severe morbidity. The approval follows a double-blind, randomized, placebo-controlled MANEUVER trial that evaluated pimicotinib 50 mg once daily.
Primary source
FDA approval notification, November 10, 2026
FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor
Read the source: FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor fda.gov
Machine-summarized from the source above; not independently reported. How we use automation